Vertex Pharmaceuticals announced the first accepted medical presentations of the Phase 3 data on the investigational once ...

Vertex Pharmaceuticals Inc. closed $47.49 short of its 52-week high ($510.64), which the company reached on August 1st.

Management is planning to accelerate growth by investing 20% more in its brands than last year. Kenvue may not be a fast ...

Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This ...

The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

The studies are among a handful of pioneering trials using stem cells to treat diabetes, which affects close to half a ...

Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) announced Thursday that Health Canada has accepted for review its New Drug ...

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and ...

Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...

Vertex Pharmaceuticals Inc. (VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene ...

Last December, the FDA approved two additional treatments for SCD—Casgevy™ (“exa-cel” or exagamglogene autotemcel), the first ...